Classical Hodgkin Lymphoma
Clinical research activity includes relapsed or refractory classical Hodgkin lymphoma, with interest in treatment settings where disease has progressed after prior therapy and in patients requiring non-standard options.
- Ruxolitinib combinations
- Brentuximab
- Pembrolizumab
The focus is on achieving deeper complete response outcomes in heavily pretreated lymphoma.
Hairy Cell Leukemia
Research efforts address hairy cell leukemia in patients needing anti-leukemic treatment after prior purine analogue exposure, including refractory disease, early relapse, intolerance, and situations where chemotherapy is unsuitable.
- Vemurafenib
- Cobimetinib
- Obinutuzumab
- BRAF-V600E mutation
These studies explore step-wise targeted and antibody-based treatment strategies for anti-leukemic activity.
Front-line Hairy Cell Leukemia
The sponsor also investigates first-line management of hairy cell leukemia, with attention to chemotherapy-free alternatives and treatment approaches guided by disease control and response assessment.
- Cladribine alternatives
- Rituximab
- Minimal residual disease guidance
This area reflects interest in reducing reliance on conventional cytotoxic therapy while maintaining disease control.
Cutaneous Malignant Melanoma
Clinical trials also cover cutaneous malignant melanoma after radical surgery, including patients with higher-risk disease stages where immunotherapy is used in the adjuvant setting.
- Stage IIb-c melanoma
- Stage III melanoma
- Stage IV melanoma
The research examines postoperative treatment duration and disease-free control in high-risk melanoma.
